Radiation after surgery for lung cancer that spread to lymph nodes
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if giving radiation after surgery can help people with non-small cell lung cancer that has spread to multiple lymph nodes in the chest. It may offer a treatment option for those who have not had chemotherapy or immunotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have non-small cell lung cancer that spread to at least 3 lymph nodes in the chest after surgery.
- You have not had radiation, chemotherapy, or immunotherapy before.
- You are in reasonably good health and can take care of yourself (ECOG 0-2).
- Your major organs like bone marrow, liver, and kidneys are working well.
- You do not have an active autoimmune disease or condition that weakens your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether giving radiation therapy after surgery can help prevent lung cancer from coming back in people who have already had chemotherapy and immunotherapy before surgery. It is for patients whose cancer had spread to chest lymph nodes and who still have some cancer left in those nodes after surgery.
This trial tests whether giving a combination of two targeted drugs (tislelizumab and anlotinib) plus standard chemotherapy before and after surgery can help people with early-stage lung cancer. The goal is to see if this approach can shrink the tumor and lower the chance of the cancer coming back.
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
This trial tests a combination of immunotherapy (tislelizumab) followed by surgery and radiation for people with a specific type of advanced lung cancer (N3 stage NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.